Diagnosis of malignant autoimmune myasthenia gravis is a dubious disease in the field of the nervous system, clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical treatment are essential for improving prognosis. Diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can help to align national and international experts and teams to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many diseases of the nervous system that have previously been difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of malignant autoimmune myasthritis. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.